by Micah Harman | Jan 17, 2025 | News & Media, Interviews/Speaking/Events
Executives attending J.P. Morgan conference don’t expect to find easy money in 2025 By Rowan Walrath C&EN Cartography Biosciences CEO Kevin Parker doesn’t see 2025 being much better than 2024 when it comes to financing opportunities for biotechnology companies... by Micah Harman | Jan 8, 2025 | Press Releases, Interviews/Speaking/Events, News & Media
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel... by Micah Harman | Jan 6, 2025 | News & Media
See today’s BioWorld New hires and promotions in the biopharma industry, including: Amylyx, Beigene, Blossomhill, Halia, Iambic, Perspective, Portage, Septerna, Unity. Amylyx Pharmaceuticals Inc., of Cambridge, Mass., named Dan Monahan chief commercial officer.... by Micah Harman | Jan 6, 2025 | News & Media
Utah Business is proud to present the 2024 Year in Review. This recap features notable news, M&A activity and closed funding rounds within Utah’s business community in January 2024. By Mekenna Malan, Melanie Jones and Savannah Beth Withers Taylor Jan 3, 2025... by Micah Harman | Dec 18, 2024 | News & Media, Interviews/Speaking/Events
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS. Jordyn Sava December 17, 2024 The second stage of a phase 2 trial exploring the first-in-class allosteric... by Micah Harman | Dec 12, 2024 | News & Media
Read this article on the website US biotech Halia Therapeutics has announced promising topline findings from its ongoing Phase 2 clinical trial of its oral treatment for lower-risk myelodysplastic syndromes. The drug, HT-6184, targets the NEK7 protein, which is... by Micah Harman | Dec 12, 2024 | News & Media
Read this article on the website Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initialpositive data in patients with an early form of blood cancer that affects the bone marrow. The Utah-based biotech is investigating... by Micah Harman | Nov 13, 2024 | Interviews/Speaking/Events, News & Media
David Wild interviews David Bearss, CEO of Halia Therapeutics Read the article here by Micah Harman | Oct 18, 2024 | News & Media
https://slenterprise.com/index.php/news/7714-industry-briefs-10-21-24 RECOGNITIONS This year’s PharmaVoice 100 honorees list includes David Bearss, CEO, president and co-founder of Halia Therapeutics, a Lehi-based company developing therapies addressing chronic... by Micah Harman | Oct 16, 2024 | Interviews/Speaking/Events, News & Media
BIO News BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Clary Estes October 15, 2024 There is a great degree of renewed optimism for drug... by Micah Harman | Oct 8, 2024 | Press Releases, News & Media
LEHI, Utah, Oct. 8, 2024 /PRNewswire/ — Dr. David Bearss, CEO and Co-founder of Halia Therapeutics has been named an honoree of the 2024 PharmaVoice 100 list in the Standout Leaders category. This prestigious recognition... by Halia Therapeutics | Oct 4, 2024 | News & Media, Interviews/Speaking/Events
Listen to Dr David Bearss discuss Halia’s work on Alzheimer’s and other inflammation-related diseases https://podcasts.apple.com/us/podcast/dr-dave-bearss-co-founder-ceo-of-halia-on-pioneering/id1482108463?i=1000671780322 Explore the forefront of biotech... by Halia Therapeutics | Sep 29, 2024 | News & Media
Combination with NLRP3 inhibitor achieves 50% greater weight loss and lean muscle preservation in mice than with semaglutide alone. As featured in Longevity.Technology “Inflammation-targeting biotech Halia Therapeutics has reported promising preclinical results... by Halia Therapeutics | Sep 23, 2024 | News & Media
https://podcast.labiotech.eu/1995493/episodes/15734215-targeting-inflammation-a-revolution-in-disease-treatment Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.... by Halia Therapeutics | Sep 16, 2024 | News & Media
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for “Best Digital Health Solution,” “Best Medical Technology,” and... by Halia Therapeutics | Sep 3, 2024 | News & Media, Interviews/Speaking/Events
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart... by Micah Harman | Jul 15, 2024 | News & Media
By Jill Drachenberg — BioSpace July 15, 2024 Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression. Preventing or reversing neuroinflammation could be the next clinical... by Micah Harman | Jun 26, 2024 | News & Media
Charleston, South Carolina, June 5, 2024 – John Kauwe Ph.D., a 2013 CCAD awardee shares how CCAD made a difference in his research career. Kauwe is the president of BYU-Hawaii and owner of Halia Therapeutics, a company that discovers and develops novel... by Micah Harman | Jun 14, 2024 | News & Media
By Joe Petroziello — Pharmaceutical Executive June 13, 2024 Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions. During BIO International Convention 2024, CEO Dave Bearss, PhD, of... by Micah Harman | Jun 14, 2024 | News & Media
Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the inflammatory...